494 related articles for article (PubMed ID: 19533750)
41. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
42. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N; Coley HM; Sehouli J; Koensgen D; Mustea A; Szlosarek P; McNeish I; Blagden SP; Schmid P; Lovell DP; Hatzimichael E; Crook T
Cancer Res; 2011 May; 71(9):3317-27. PubMed ID: 21402713
[TBL] [Abstract][Full Text] [Related]
43. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S; Meier W; du Bois A; Brown C; Lorusso D; Dell'Anna T; Cretin J; Havsteen H; Bessette P; Zeimet AG; Vergote I; Vasey P; Pujade-Lauraine E; Gladieff L; Ferrero A
Eur J Cancer; 2015 Feb; 51(3):352-8. PubMed ID: 25534295
[TBL] [Abstract][Full Text] [Related]
44. Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy.
Tsai CY; Chi HC; Chi LM; Yang HY; Tsai MM; Lee KF; Huang HW; Chou LF; Cheng AJ; Yang CW; Wang CS; Lin KH
FASEB J; 2018 May; 32(5):2601-2614. PubMed ID: 29401583
[TBL] [Abstract][Full Text] [Related]
45. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
46. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
[TBL] [Abstract][Full Text] [Related]
47. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract][Full Text] [Related]
48. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1.
Locke M; Ghazaly E; Freitas MO; Mitsinga M; Lattanzio L; Lo Nigro C; Nagano A; Wang J; Chelala C; Szlosarek P; Martin SA
Cell Rep; 2016 Aug; 16(6):1604-1613. PubMed ID: 27452468
[TBL] [Abstract][Full Text] [Related]
50. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
51. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
52. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers.
Kremer JC; Prudner BC; Lange SES; Bean GR; Schultze MB; Brashears CB; Radyk MD; Redlich N; Tzeng SC; Kami K; Shelton L; Li A; Morgan Z; Bomalaski JS; Tsukamoto T; McConathy J; Michel LS; Held JM; Van Tine BA
Cell Rep; 2017 Jan; 18(4):991-1004. PubMed ID: 28122247
[TBL] [Abstract][Full Text] [Related]
53. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
[TBL] [Abstract][Full Text] [Related]
54. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
Perego P; Romanelli S; Carenini N; Magnani I; Leone R; Bonetti A; Paolicchi A; Zunino F
Ann Oncol; 1998 Apr; 9(4):423-30. PubMed ID: 9636834
[TBL] [Abstract][Full Text] [Related]
55. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
56. Chemotherapy of advanced ovarian cancer.
Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
[TBL] [Abstract][Full Text] [Related]
57. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
58. Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
Flanagan JM; Wilson A; Koo C; Masrour N; Gallon J; Loomis E; Flower K; Wilhelm-Benartzi C; Hergovich A; Cunnea P; Gabra H; Braicu EI; Sehouli J; Darb-Esfahani S; Vanderstichele A; Vergote I; Kreuzinger C; Castillo-Tong DC; Wisman GBA; Berns EM; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2017 May; 23(9):2213-2222. PubMed ID: 27663594
[No Abstract] [Full Text] [Related]
59. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
60. Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance.
Lan J; Tai HC; Lee SW; Chen TJ; Huang HY; Li CF
Tumour Biol; 2014 Jan; 35(1):161-9. PubMed ID: 23897555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
